Profile
Sector:
HealthcareCountry:
LuxembourgIPO:
09 December 2019Website:
http://www.procapsgroup.comNext earnings report:
26 December 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:10:16 GMTDividend
Analysts recommendations
Institutional Ownership
PROC Latest News
MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced today that, on November 13, 2024, the Company received formal notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company's failure to timely file the Form 20-F for the fiscal year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (the “SEC”), the Company no longer satisfied Nasdaq Listing Rule 5250(c)(1) (the “Filing Rule”) and its securities are therefore subject to suspension and delisting unless the Company timely requests a hearing before and a further stay of any suspension action at least pending the ultimate conclusion of the hearings process from the Nasdaq Hearings Panel (the “Panel”).
MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, providing critical updates on the Company's ongoing independent investigation, financial restatement, governance enhancements, and commitment to long-term stability.
COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) treated with TransCon IL-2 β/γ in combination with chemotherapy in its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β/γ. First results will be shared in Poster 762P at ESMO 2024, the annual meeting of the European Society of Medical Oncology being held in Barcelona from September 13-17, 2024.
MIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, addressing the current state of the business and outlining key strategic priorities for the Company.
Procaps Group, S.A. (PROC) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share.
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Report Third Quarter and Nine Months Results on Tuesday November 14 and Host Conference Call on Thursday November 16 at 10:30a.m. ET.
Procaps Group, S.A. (PROC) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.06 per share.
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Report Second Quarter and First Half 2023 Results and Host Conference Call on Tuesday.
MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will file its Form 20-F and publish its Full Year 2022 Earnings Release before May 15th.
What type of business is Procaps Group SA?
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
What sector is Procaps Group SA in?
Procaps Group SA is in the Healthcare sector
What industry is Procaps Group SA in?
Procaps Group SA is in the Drug Manufacturers - Specialty & Generic industry
What country is Procaps Group SA from?
Procaps Group SA is headquartered in Luxembourg
When did Procaps Group SA go public?
Procaps Group SA initial public offering (IPO) was on 09 December 2019
What is Procaps Group SA website?
https://www.procapsgroup.com
Is Procaps Group SA in the S&P 500?
No, Procaps Group SA is not included in the S&P 500 index
Is Procaps Group SA in the NASDAQ 100?
No, Procaps Group SA is not included in the NASDAQ 100 index
Is Procaps Group SA in the Dow Jones?
No, Procaps Group SA is not included in the Dow Jones index
When was Procaps Group SA the previous earnings report?
No data
When does Procaps Group SA earnings report?
The next expected earnings date for Procaps Group SA is 26 December 2024